Estimating the residual risk for HIV, HCV and HBV in different types of platelet concentrates in Germany

Vox Sanguinis

Volumn 108, Issue 2, 2015, Pages 123-130

  An der Heiden, M ^a   Ritter, S ^a   Hamouda, O ^a   Offergeld, R ^a  

^a ROBERT KOCH INSTITUTE   (Germany)

Author keywords

Blood transfusion; Platelet concentrates; Residual risk; Window period

Indexed keywords

THROMBOCYTE CONCENTRATE;

APHERESIS; ARTICLE; BLOOD DONOR; BLOOD TRANSFUSION; FEMALE; GERMANY; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; INFECTION RISK; MALE; PRIORITY JOURNAL; RISK ASSESSMENT; ADOLESCENT; ADULT; ADVERSE EFFECTS; BLOOD SAFETY; CLASSIFICATION; HEPATITIS B; HEPATITIS C; HIV INFECTIONS; INCIDENCE; MIDDLE AGED; PREVALENCE; RISK; STANDARDS; THROMBOCYTE; VIROLOGY;

ADOLESCENT; ADULT; BLOOD DONORS; BLOOD PLATELETS; BLOOD SAFETY; BLOOD TRANSFUSION; FEMALE; GERMANY; HEPATITIS B; HEPATITIS C; HIV INFECTIONS; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PREVALENCE; RISK;

EID: 84921056918     PISSN: 00429007     EISSN: 14230410     Source Type: Journal    
DOI: 10.1111/vox.12204     Document Type: Article

References (37)

1. Paul-Ehrlich-Institut: Tabelle zur Meldung nach § 21 Transfusionsgesetz für das Jahr 2012, http://www.pei.de/DE/infos/meldepflichtige/meldung-blutprodukte-21-transfusionsgesetz/berichte/berichte-21tfg-node.html#doc3258776bodyText1 (last accessed: 02.09.14)
2. Haschberger B, Henseler O, Hesse J, et al.: Report on notifications pursuant to section 21 German transfusion act for 2005 and 2006. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2008; 51:353-372
3. Henseler O, Heiden M, Haschberger B, et al.: Report on notifications pursuant to § 21 German transfusion act for 2007. Transfus Med Hemother 2010; 37:29-47
4. Henseler O, Heiden M, Haschberger B, et al.: Report on notifications pursuant to § 21 German transfusion act for 2008 and 2009. Transfus Med Hemother 2011; 38:199-216
5. Henseler O, Heiden M, Haschberger B, et al.: Report on notifications pursuant to § 21 German transfusion act for 2010 and 2011. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2013; 56:1352-1367
6. Lozano ML, Rivera J, Vicente V: Platelet concentrates from whole-blood donations (buffy-coat) or apheresis: which one to use? Med Clin 2012; 138:528-533
7. Schrezenmeier H, Seifried E: Buffy-coat-derived pooled platelet concentrates and apheresis platelet concentrates: which product type should be preferred? Vox Sang 2010; 99:1-15
8. Zimmermann R, Blasczyk R, Zingsem J, et al.: Disparate risks and effects of pooled whole blood-derived vs. apheresis platelet production require an integral view on the blood supply. Vox Sang 2010; 99:295-296; author reply 7-8.
9. Xiao W, Tormey CA, Capetillo A, et al.: Allergic transfusion reactions to platelets are more commonly associated with prepooled than apheresis components. Vox Sang 2013; 105:334-340
10. van der Meer PF: Platelet concentrates, from whole blood or collected by apheresis? Transfus Apher Sci 2013; 48:129-131
11. Vamvakas EC, Hitzler WE: Consistency and proportionality in policy decision-making in blood safety: the case for an all-apheresis platelet supply in Germany. Clin Lab 2013; 59:1-22
12. Thiele T, Heddle N, Greinacher A: Donor exposures in recipients of pooled platelet concentrates. N Engl J Med 2013; 368:487-489
13. Schreiber GB, Busch MP, Kleinman SH, et al.: The risk of transfusion-transmitted viral infections. The Retrovirus Epidemiology Donor Study. N Engl J Med 1996; 334:1685-1690
14. Seed CR, Chang A, Ismay SL, et al.: Assessing the accuracy of three viral risk models in predicting the outcome of implementing HIV and HCV NAT donor screening in Australia and the implications for future HBV NAT. Transfusion 2002; 42:1365-1372
15. Wang J, Liu J, Yao F, et al.: Prevalence, incidence, and residual risks for transfusion-transmitted human immunodeficiency virus Types 1 and 2 infection among Chinese blood donors. Transfusion 2013; 53:1240-1249
16. de Almeida-Neto C, Sabino EC, Liu J, et al.: Prevalence of serologic markers for hepatitis B and C viruses in Brazilian blood donors and incidence and residual risk of transfusion transmission of hepatitis C virus. Transfusion 2013; 53:827-834
17. Sabino EC, Goncalez TT, Carneiro-Proietti AB, et al.: Human immunodeficiency virus prevalence, incidence and residual risk of transmission by transfusion at retrovirus Epidemiology Donor Study-II blood centers in Brazil. Transfusion 2012; 52:870-879
18. O'Brien SF, Yi QL, Fan W, et al.: Current incidence and residual risk of HIV, HBV and HCV at Canadian blood services. Vox Sang 2012; 103:83-86
19. Yasui Y, Yanai H, Sawanpanyalert P, et al.: A statistical method for the estimation of window-period risk of transfusion-transmitted HIV in donor screening under non-steady state. Biostatistics 2002; 3:133-143
20. Richtlinien zur Gewinnung von Blut und Blutbestandteilen und zur Anwendung von Blutprodukten (Haemotherapie). BAnz 2010; 101a.
21. Offergeld R, Ritter S, Hamouda O: HIV, HCV, HBV and syphilis surveillance among blood donors in Germany 2008-2010. Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz 2012; 55:907-913
22. Offergeld R, Ritter S, Quabeck L, et al.: Epidemiological data on infections among blood donors in Germany 2007. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2010; 53:1188-1196
23. Willand L, Ritter S, Reinhard B, et al.: HIV, HCV, HBV and syphilis infections among blood donors in Germany 2006. Report from the Robert Koch Institute in accordance with Article 22 of the Transfusion Act. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2008; 51:902-914
24. Hourfar MK, Jork C, Schottstedt V, et al.: Experience of German Red Cross blood donor services with nucleic acid testing: results of screening more than 30 million blood donations for human immunodeficiency virus-1, hepatitis C virus, and hepatitis B virus. Transfusion 2008; 48:1558-1566
25. Offergeld R, Faensen D, Ritter S, et al.: Human immunodeficiency virus, hepatitis C and hepatitis B infections among blood donors in Germany 2000-2002: risk of virus transmission and the impact of nucleic acid amplification testing. Euro Surveill 2005; 10:8-11
26. Keller-Stanislawski B, Lohmann A, Gunay S, et al.: The German Haemovigilance System-reports of serious adverse transfusion reactions between 1997 and 2007. Transfus Med 2009; 19:340-349
27. Chudy M, Weber-Schehl M, Pichl L, et al.: Blood screening nucleic acid amplification tests for human immunodeficiency virus Type 1 may require two different amplification targets. Transfusion 2012; 52:431-923
28. RKI: Virushepatitis im Jahr 2012. Epid Bull 2012; 30:273-280
29. RKI: HIV-Infektionen und AIDS-Erkrankungen in Deutschland. Epid Bull 2014; 26:214-232
30. Hitzler WE: Single-donor (apheresis) platelets and pooled whole blood derived platelets - significance and assessment of both blood products. Clin Lab 2014; 60:1-39
31. Busch MP, Glynn SA, Stramer SL, et al.: A new strategy for estimating risks of transfusion-transmitted viral infections based on rates of detection of recently infected donors. Transfusion 2005; 45:254-264
32. Announcement of the National Advisory Committee: "Blood" (Arbeitskreis Blut) of the German federal Ministry of Health: lookback procedure. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2006; 49:940-957
33. Ritter S, Hamouda O, Offergeld R: Demography and donation frequencies of blood and plasma donor populations in Germany. Update 2010 and 5-year comparison. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2012; 55:914-922
34. Weusten JJ, van Drimmelen HA, Lelie PN: Mathematic modeling of the risk of HBV, HCV, and HIV transmission by window-phase donations not detected by NAT. Transfusion 2002; 42:537-548
35. Busch MP, Murthy KK, Kleinman SH, et al.: Infectivity in chimpanzees (Pan troglodytes) of plasma collected before HCV RNA detectability by FDA-licensed assays: implications for transfusion safety and HCV infection outcomes. Blood 2012; 119:6326-6334
36. Bruhn R, Lelie N, Custer B, et al.: Prevalence of human immunodeficiency virus RNA and antibody in first time, lapsed and repeat blood donations across five international regions and relative efficacy of alternative screening scenarios. Transfusion 2013; 53:2399-2412
37. Heuft HG, Mende W, Blasczyk R: A general change of the platelet transfusion policy from apheresis platelet concentrates to pooled platelet concentrates is associated with a sharp increase in donor exposure and infection rates. Transfus Med Hemother 2008; 35:106-113